The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinoiin-6-yiamino)-1-oxopropan-2-yi)benzyi 2,4-dirnethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.